Imagine millions of people in the UK trapped in a cycle of dependency, not on drugs or alcohol, but on something as seemingly harmless as a nasal spray. It sounds unbelievable, but it’s a growing concern, as an ITV News and Ipsos survey reveals. The findings are alarming: over a fifth of those using decongestant nasal sprays have been doing so for longer than the recommended seven days, putting them at risk of a condition called rebound congestion. This isn’t just about a stuffy nose—it’s a vicious cycle where overuse leads to worsening symptoms, driving users to rely on the spray even more. But here’s where it gets controversial: while the NHS and manufacturers warn against prolonged use, many users remain unaware of the risks, and some GPs seem equally uninformed. Could clearer labeling and better education be the solution, or is this a deeper issue of self-medication gone wrong?
Rebound congestion, also known as rhinitis medicamentosa, is triggered by nasal sprays containing xylometazoline and oxymetazoline. Unlike steroid or saline sprays, these decongestants can lead to dependency if overused. The problem? Many users, like 30-year-old Charlotte Johnstone, have been using these sprays for years without realizing the long-term consequences. Charlotte, who’s been using the spray multiple times a day since she was seven, shared her harrowing experience: ‘I can’t sleep without it. I wake up, and the first thing I do is reach for my nasal spray.’ Her dependence has caused anxiety, nightmares about not being able to breathe, and even periods of losing her sense of smell. Yet, she feels trapped, unwilling to face the daunting prospect of quitting cold turkey.
Charlotte’s story isn’t unique. After ITV News’ initial report, thousands reached out with similar tales of struggle. One person described six months of blocked nostrils after overuse, calling it ‘the worst six months of my life.’ Another admitted to having panic attacks if they forget their spray. And this is the part most people miss: some GPs have dismissed these concerns, leaving patients feeling invalidated. One person shared, ‘I went to the GP because of my dependency, and she laughed in my face.’
The Royal Pharmaceutical Society has taken notice, launching a survey that highlights the need for clearer product labeling. Nearly three-quarters of pharmacists believe the seven-day limit should be more prominently displayed, and 63% have had to intervene with patients showing signs of overuse. Professor Amira Guirguis, Chief Scientist at the RPS, emphasizes the urgency: ‘We need a clear warning on the front of the packaging to prevent further harm.’ Alternatives like saline rinses, nasal strips, and steam inhalation are recommended, but breaking the cycle isn’t easy. As Charlotte puts it, ‘Going cold turkey is scary—I’d have to take time off work just to cope.’
Manufacturers, represented by PAGB, argue that patient information leaflets already outline the risks. But is this enough? With an estimated 5.5 million people in the UK potentially at risk, the question remains: Are we doing enough to prevent this silent dependency? And here’s a thought-provoking question for you: Should nasal sprays with addiction potential be regulated more strictly, or is it the responsibility of users and healthcare providers to stay informed?
If you’ve experienced similar struggles, share your story by emailing investigations@itv.com. Let’s keep the conversation going—because this isn’t just about a nasal spray; it’s about awareness, education, and preventing millions from falling into an avoidable trap. For more insights, subscribe to our weekly newsletter or listen to our podcasts for expert briefings on the stories that matter.
